Cite
HARVARD Citation
Tobback, E. et al. (2022). Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial. International journal of infectious diseases. pp. 628-635. [Online].